ID

26748

Beschreibung

Study Part: Pre-dose Checklist Week 5 PK Visit (Visit 9). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Stichworte

  1. 23.10.17 23.10.17 -
Rechteinhaber

GlaxoSmithKline

Hochgeladen am

23. Oktober 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Pre-dose Checklist Week 5 PK Visit (Visit 9) Ropinirole Parkinson Disease 101468/165

Pre-dose Checklist Week 5 PK Visit (Visit 9)

PREDOSE CHECKLIST
Beschreibung

PREDOSE CHECKLIST

Alias
UMLS CUI-1
C0439565
UMLS CUI-2
C1707357
Patient Number
Beschreibung

Patient Number

Datentyp

text

Alias
UMLS CUI [1]
C1830427
Centre Number
Beschreibung

Centre Number

Datentyp

integer

Alias
UMLS CUI [1,1]
C0600091
UMLS CUI [1,2]
C0019994
Visit Date
Beschreibung

Visit Date

Datentyp

date

Alias
UMLS CUI [1]
C1320303
1. Has the patient refrained from consuming alcohol for 24 hours prior to the clinic visit?
Beschreibung

alcohol consumption

Datentyp

boolean

Alias
UMLS CUI [1]
C0001948
2. Has the patient tried to refrain from consuming xanthine-containing beverage and foods (coffee, tea, cola beverages, cocoa, chocolate), grapefruit-containing products, quinine-containing products and food containing CYP1A2-inducing constituents (broccoli, bussels sprouts, cabbage etc.) within 24 hours of the clinic visit?
Beschreibung

xanthine-containing beverage and foods

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0043314
UMLS CUI [1,2]
C0016452
3. Has the patient refrained from consuming poppy seed-containing food (e.g. poppy cake) for three days before the clinic visit?
Beschreibung

poppy seed-containing food

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0453264
UMLS CUI [1,2]
C0016452
4. Has the patient maintained their normal smoking practice?
Beschreibung

smoking history

Datentyp

text

Alias
UMLS CUI [1]
C1519384
5. Has the subject had at least 3 sequential days of dosing?
Beschreibung

dosage

Datentyp

text

Alias
UMLS CUI [1]
C0178602
6. If the patient is already taking a drug known to substantially inhibit CYP1A2 or induce CYP1A2, has the patient remained on stable doses of the agent from 7 days prior to dosing with study medication?
Beschreibung

CYP1A2 inhibitors or inducers

Datentyp

text

Alias
UMLS CUI [1,1]
C1827504
UMLS CUI [1,2]
C1827490
Comments:
Beschreibung

Comments

Datentyp

text

Alias
UMLS CUI [1]
C0947611

Ähnliche Modelle

Pre-dose Checklist Week 5 PK Visit (Visit 9)

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
PREDOSE CHECKLIST
C0439565 (UMLS CUI-1)
C1707357 (UMLS CUI-2)
Patient Number
Item
Patient Number
text
C1830427 (UMLS CUI [1])
Centre Number
Item
Centre Number
integer
C0600091 (UMLS CUI [1,1])
C0019994 (UMLS CUI [1,2])
Visit Date
Item
Visit Date
date
C1320303 (UMLS CUI [1])
alcohol consumption
Item
1. Has the patient refrained from consuming alcohol for 24 hours prior to the clinic visit?
boolean
C0001948 (UMLS CUI [1])
xanthine-containing beverage and foods
Item
2. Has the patient tried to refrain from consuming xanthine-containing beverage and foods (coffee, tea, cola beverages, cocoa, chocolate), grapefruit-containing products, quinine-containing products and food containing CYP1A2-inducing constituents (broccoli, bussels sprouts, cabbage etc.) within 24 hours of the clinic visit?
boolean
C0043314 (UMLS CUI [1,1])
C0016452 (UMLS CUI [1,2])
poppy seed-containing food
Item
3. Has the patient refrained from consuming poppy seed-containing food (e.g. poppy cake) for three days before the clinic visit?
boolean
C0453264 (UMLS CUI [1,1])
C0016452 (UMLS CUI [1,2])
Item
4. Has the patient maintained their normal smoking practice?
text
C1519384 (UMLS CUI [1])
Code List
4. Has the patient maintained their normal smoking practice?
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
N/A (N/A)
Item
5. Has the subject had at least 3 sequential days of dosing?
text
C0178602 (UMLS CUI [1])
Code List
5. Has the subject had at least 3 sequential days of dosing?
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
N/A (N/A)
Item
6. If the patient is already taking a drug known to substantially inhibit CYP1A2 or induce CYP1A2, has the patient remained on stable doses of the agent from 7 days prior to dosing with study medication?
text
C1827504 (UMLS CUI [1,1])
C1827490 (UMLS CUI [1,2])
Code List
6. If the patient is already taking a drug known to substantially inhibit CYP1A2 or induce CYP1A2, has the patient remained on stable doses of the agent from 7 days prior to dosing with study medication?
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
N/A (N/A)
Comments
Item
Comments:
text
C0947611 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video